1. Home
  2. COLL vs PRG Comparison

COLL vs PRG Comparison

Compare COLL & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • PRG
  • Stock Information
  • Founded
  • COLL 2002
  • PRG 2020
  • Country
  • COLL United States
  • PRG United States
  • Employees
  • COLL N/A
  • PRG N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • PRG Diversified Commercial Services
  • Sector
  • COLL Health Care
  • PRG Consumer Discretionary
  • Exchange
  • COLL Nasdaq
  • PRG Nasdaq
  • Market Cap
  • COLL 958.8M
  • PRG 1.1B
  • IPO Year
  • COLL 2015
  • PRG N/A
  • Fundamental
  • Price
  • COLL $32.38
  • PRG $30.25
  • Analyst Decision
  • COLL Strong Buy
  • PRG Strong Buy
  • Analyst Count
  • COLL 4
  • PRG 5
  • Target Price
  • COLL $43.75
  • PRG $41.80
  • AVG Volume (30 Days)
  • COLL 306.9K
  • PRG 371.0K
  • Earning Date
  • COLL 08-07-2025
  • PRG 07-23-2025
  • Dividend Yield
  • COLL N/A
  • PRG 1.73%
  • EPS Growth
  • COLL N/A
  • PRG 99.08
  • EPS
  • COLL 1.25
  • PRG 4.90
  • Revenue
  • COLL $664,283,000.00
  • PRG $2,505,714,000.00
  • Revenue This Year
  • COLL $20.04
  • PRG $1.36
  • Revenue Next Year
  • COLL $3.98
  • PRG $4.29
  • P/E Ratio
  • COLL $25.16
  • PRG $6.14
  • Revenue Growth
  • COLL 17.17
  • PRG 4.62
  • 52 Week Low
  • COLL $23.23
  • PRG $23.50
  • 52 Week High
  • COLL $42.29
  • PRG $50.28
  • Technical
  • Relative Strength Index (RSI)
  • COLL 71.18
  • PRG 57.83
  • Support Level
  • COLL $30.60
  • PRG $29.57
  • Resistance Level
  • COLL $31.99
  • PRG $30.81
  • Average True Range (ATR)
  • COLL 0.80
  • PRG 0.84
  • MACD
  • COLL 0.17
  • PRG 0.08
  • Stochastic Oscillator
  • COLL 95.50
  • PRG 77.47

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: